China SXT Pharmaceuticals, Inc. key statistics and ratios

In fiscal 2026, China SXT Pharmaceuticals, Inc. had return on equity of -27.5%, an operating margin of -625.9%, debt equal to 3.4% of equity and a current ratio of 7.93. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

China SXT Pharmaceuticals, Inc.: financial ratios, annual
Fiscal year	2017Mar 2017	2018Mar 2018	2019Mar 2019	2020Mar 2020	2021Mar 2021	2022Mar 2022	2023Mar 2023	2024Mar 2024	2025Mar 2025	2026Mar 2026
Gross margin	47.4%	48.5%	65.8%	52.4%	59.4%	48.1%	21.6%	28.7%	21.1%	21.9%
Operating margin	32.8%	23.3%	25.2%	−26.0%	−46.0%	−199.4%	−284.4%	−130.4%	−154.0%	−625.9%
Net margin	24.3%	16.9%	22.0%	−199.3%	−57.5%	−220.4%	−301.0%	−160.7%	−189.8%	−545.2%
Free-cash-flow margin	2.3%	21.1%	−4.2%	15.6%	−29.2%	8.0%	—	−100.3%	−134.8%	−353.0%
Return on equity	64.0%	46.2%	21.4%	−100.3%	−21.7%	−35.8%	−38.6%	−21.7%	−22.5%	−27.5%
Return on assets	—	15.5%	12.3%	−52.5%	−9.8%	−16.8%	−18.8%	−11.8%	−14.8%	−22.0%
Asset turnover	—	0.92	0.56	0.26	0.17	0.08	0.06	0.07	0.08	0.04
Current ratio	—	1.40	2.47	1.60	1.25	1.31	1.35	1.60	3.54	7.93
Debt to equity	0.0%	11.7%	2.5%	71.1%	0.3%	0.1%	0.9%	1.0%	0.7%	3.4%
Interest cover (operating income ÷ interest)	39.7x	—	—	n/m	n/m	n/m	n/m	n/m	n/m	n/m
Effective tax rate	25.0%	27.0%	14.1%	—	—	—	—	—	—	—
R&D as % of revenue	—	—	—	—	—	14.1%	10.2%	9.6%	—	—
Capital spending as % of revenue	3.7%	6.2%	7.6%	2.5%	1.6%	2.3%	—	0.4%	0.1%	0.0%
Free cash flow ÷ net income	9.6%	125.0%	−19.3%	—	—	—	—	—	—	—

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

4 of 7 checks passed · March 31, 2026

What it owns · $35m

Short-term assets $35mLonger-term assets $0m

What it owes, and who funded it · $35m

Short-term liabilities $4mLonger-term liabilities $1mShareholders' equity $30m

Short-term assets cover short-term liabilities $35m of assets due within a year against $4m of liabilities due within a year.
Short-term assets cover long-term liabilities $35m short-term assets against $697,832 of longer-dated liabilities.
More cash than debt $28m of cash against $999,565 of debt.
Debt below 40% of shareholders' equity Debt is 3% of equity.
Debt burden no higher than five years ago Debt to equity moved from 0% to 3% over five years.
A year's operating cash flow covers at least 20% of debt −$4m of operating cash flow against $999,565 of debt.
Operating profit covers interest at least five times over Operating income of −$7m against $62,965 of interest.

From China SXT Pharmaceuticals, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: SXTC vs SXTP LPCN vs SXTC SCNX vs SXTC NTRB vs SXTC

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from China SXT Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to China SXT Pharmaceuticals, Inc.